GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fate Therapeutics Inc (NAS:FATE) » Definitions » Shiller PE Ratio

Fate Therapeutics (Fate Therapeutics) Shiller PE Ratio : (As of May. 09, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Fate Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Fate Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Fate Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fate Therapeutics Shiller PE Ratio Chart

Fate Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Fate Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Fate Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Fate Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fate Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fate Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Fate Therapeutics's Shiller PE Ratio falls into.



Fate Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Fate Therapeutics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Fate Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.45/129.4194*129.4194
=-0.450

Current CPI (Dec. 2023) = 129.4194.

Fate Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.340 99.695 -0.441
201406 -0.300 100.560 -0.386
201409 -0.320 100.428 -0.412
201412 -0.300 99.070 -0.392
201503 -0.380 99.621 -0.494
201506 -0.330 100.684 -0.424
201509 -0.240 100.392 -0.309
201512 -0.260 99.792 -0.337
201603 -0.290 100.470 -0.374
201606 -0.290 101.688 -0.369
201609 -0.270 101.861 -0.343
201612 -0.210 101.863 -0.267
201703 -0.240 102.862 -0.302
201706 -0.230 103.349 -0.288
201709 -0.260 104.136 -0.323
201712 -0.290 104.011 -0.361
201803 -0.270 105.290 -0.332
201806 -0.370 106.317 -0.450
201809 -0.310 106.507 -0.377
201812 -0.250 105.998 -0.305
201903 -0.300 107.251 -0.362
201906 -0.360 108.070 -0.431
201909 -0.400 108.329 -0.478
201912 -0.370 108.420 -0.442
202003 -0.440 108.902 -0.523
202006 -0.350 108.767 -0.416
202009 -0.680 109.815 -0.801
202012 -0.610 109.897 -0.718
202103 -0.480 111.754 -0.556
202106 -0.580 114.631 -0.655
202109 -0.450 115.734 -0.503
202112 -0.720 117.630 -0.792
202203 -0.680 121.301 -0.726
202206 -0.790 125.017 -0.818
202209 -0.860 125.227 -0.889
202212 -0.580 125.222 -0.599
202303 -0.190 127.348 -0.193
202306 -0.540 128.729 -0.543
202309 -0.460 129.860 -0.458
202312 -0.450 129.419 -0.450

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Fate Therapeutics  (NAS:FATE) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Fate Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Fate Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Fate Therapeutics (Fate Therapeutics) Business Description

Traded in Other Exchanges
Address
12278 Scripps Summit Drive, San Diego, CA, USA, 92131
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Executives
J Scott Wolchko director, officer: President and CEO C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Dulac Edward J Iii officer: Chief Financial Officer FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121
Bahram Valamehr officer: Chief Development Officer C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, STE 200, SAN DIEGO CA 92121
Cindy Tahl officer: See Remarks C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, STE 200, SAN DIEGO CA 92121
Redmile Group, Llc director, 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Yuan Xu director C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Brian T. Powl officer: Chief Commercial Officer C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO CA 92131
Yu-waye Chu officer: See Remarks FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121
John Mendlein director
Mark Plavsic officer: Chief Technical Officer C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121
Shefali Agarwal director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Karin Jooss director C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Timothy P Coughlin director 339 NORTH GRANADOS AVE, SOLANA BEACH CA 92075
Robert Hershberg director 3005 FIRST AVENUE, SEATTLE WA 98121
Robert S Epstein director

Fate Therapeutics (Fate Therapeutics) Headlines

From GuruFocus